KAI Pharmaceuticals' Candidate Get Second Chance
By The PharmaDeals Team
Pharma Deals Review: Vol 2008 Issue 96 (Table of Contents)
Published: 13 May-2008
DOI: 10.3833/pdr.v2008.i96.176 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
BMS has entered into a licensing agreement for KAI Pharmaceuticals' KAI-9803, a first-in-class drug being developed to reduce the effects of a heart attack...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018